Antifungal drug resistance of pathogenic fungi

Lancet

Volumn 359, Issue 9312, 2002, Pages 1135-1144

  Kontoyiannis, Dimitrios P ^a   Lewis, Russell E ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; FLUOROPYRIMIDINE DERIVATIVE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TREATMENT OUTCOME; VIRULENCE;

EID: 0037197022     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08162-X     Document Type: Review

References (119)

1. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
2. Current and emerging azole antifungal agents
3. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches
4. Antifungal susceptibility testing: Practical aspects and current challenges
5. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
6. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
7. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
8. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
9. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
10. Amphotericin B-resistant yeast infection in severely immunocompromised patients
11. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
12. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia
13. Predictors of outcome in cancer patients with candidemia
14. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole
15. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates
16. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
17. Incidence of polyene-resistant yeasts recovered from clinical specimens
18. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
19. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice
20. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
21. Antifungal drug resistance in pathogenic fungi
22. Drug resistance in Cryptococcus neoformans
23. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
24. Resistance of Candida species to fluconazole
25. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection
26. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis
27. High prevalence of antifungal resistance in Candida spp from patients with AIDS
28. Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive in individuals prior to first thrush episode
29. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C albicans in human immunodeficiency virus- infected patients
30. Genotypic identification of sequential Candida albicans isolates from AIDS patients by polymerase chain reaction techniques
31. The ins and outs of DNA fingerprinting the infectious fungi
32. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals
33. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients
34. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
35. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection
36. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis
37. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
38. Effects of fluconazole administration in critically ill patients: Analysis of bacterial and fungal resistance
39. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women
40. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis
41. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents
42. Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole
43. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS
44. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
45. Nosocomial candidiasis: Emerging species, reservoirs and modes of transmission
46. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans
47. Fluconazole versus Candida albicans: A complex relationship
48. Increased adherence of fluconazole-resistant isolates of Candida species to explanted esophageal mucosa
49. In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus
50. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997
51. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients
52. Burden of aspergillosis-related hospitalizations in the United States
53. Antifungal drug resistance in Aspergillus
54. Acquired itraconazole resistance in Aspergillus fumigatus
55. Aspergillus fumigatus and aspergillosis
56. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B
57. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
58. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
59. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
60. Genetically controlled cross resistance to polyene antibiotics in Saccharomyces cerevisiae
61. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus
62. Antifungal chemotherapy - Are we winning?
63. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
64. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
65. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene
66. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
67. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
68. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
69. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6- desaturation
70. Reversible fluconazole resistance in Candida albicans: A potential in vitro model
71. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans
72. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans
73. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans
74. Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans
75. Itraconazole resistance in Aspergillus fumigatus
76. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus
77. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A nidulans P450 14alpha demethylase gene, pdmaA
78. Molecular mechanisms of drug resistance in fungi
79. Azole resistance in Candida
80. Transcriptional analyses of antifungal drug resistance in Candida albicans
81. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains
82. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents
83. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata
84. In-vivo selection of an azole-resistant petite mutant of Candida glabrata
85. Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
86. Molecular biological characterization of an azole-resistant Candida glabrata isolate
87. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
88. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance
89. Mechanism of fluconazole resistance in Candida krusei
90. Molecular mechanisms of azole resistance in clinical isolates of C. dubliniensis from HIV-infected patients with oropharyngeal candidiasis
91. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis
92. Susceptibilities of antifungal agents in clinical isolates of Cryptococcus neoformans and analysis of resistance mechanisms
93. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum
94. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
95. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance
96. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans
97. Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans
98. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
99. Lipid formulations of amphotericin B: Recent progress and future directions
100. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs
101. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study
102. High-dose therapy with fluconazole > or = 800 mg day-1
103. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
104. The past, present and future of antimycotic combination therapy
105. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
106. Rationale for combination antifungal therapy
107. Immunomodulation for the treatment of invasive fungal infections
108. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
109. Combination immunotherapy and antifungal chemotherapy
110. The exciting future of antifungal therapy
111. A clinical perspective for the management of invasive fungal infections: Focus on IDSA guidelines. Infectious Diseases Society of America
112. Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors
113. Antibiotics that inhibit fungal cell wall development
114. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase
115. The contribution of fluconazole to the changing epidemiology of invasive candidal infections
116. Transmission of an azole-resistant isogenic strain of Candida albicans among human immunodeficiency virus-infected family members with oropharyngeal candidiasis
117. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals